Skip to main content

NICE TAs

21/07/2020
TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
21/07/2020
TA419: Apremilast for treating moderate to severe plaque psoriasis (replaced TA368)
21/07/2020
TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
21/07/2020
TA350: Secukinumab for treating moderate to severe plaque psoriasis
21/07/2020
TA370: Bortezomib for previously untreated mantle cell lymphoma
21/07/2020
TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
14/07/2020
TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
10/06/2020
TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
10/06/2020
TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
10/06/2020
TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
10/06/2020
TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
29/05/2020
TA379: Nintedanib for treating idiopathic pulmonary fibrosis
29/05/2020
TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
29/05/2020
TA356: Ruxolitinib for treating polycythaemia vera (terminated appraisal)
29/05/2020
TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
22/05/2020
TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
22/05/2020
TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
22/05/2020
TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
18/05/2020
TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
18/05/2020
TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Follow AWTTC: